5 research outputs found
ATPS-84HYDROXYUREA SENSITIZES PATIENT-DERIVED GLIOBLASTOMA TUMORS TO TEMOZOLOMIDE IRRESPECTIVE OF MGMT STATUS
Erratum: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype (Neuro-Oncology 20:5 DOI: 10.1093/neuonc/nox198)
The authors wish to correct a mistake in Figure 1, Panel A: the label for cell SNZ308, SNZ308r1, and SNZ308r2 should be LNZ308, LNZ308r1, and LNZ308r2, respectively (Volume 20, Issue 5, doi:10.1093/neuonc/nox198)
Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype
Background Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumor. Standard-of-care treatment involves maximal surgical resection of the tumor followed by radiation and chemotherapy (temozolomide [TMZ]). The 5-year survival rate of patients with GBM is <10%, a colossal failure that has been partially attributed to intrinsic and/or acquired resistance to TMZ through O 6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the tumor. Methods A drug screening aimed at evaluating the potential recycling and repurposing of known drugs was conducted in TMZ-resistant GBM cell lines and primary cultures of newly diagnosed GBM with different MGMT promoter methylation status, phenotypic/genotypic background and subtype, and validated with sphere formation, cell migration assays, and quantitative invasive orthotopic in vivo models. Results We identified hydroxyurea (HU) to synergize with TMZ in GBM cells in culture and in vivo, irrespective of MGMT promoter methylation status, subtype, and/or stemness. HU acts specifically on the S-phase of the cell cycle by inhibiting the M2 unit of enzyme ribonucleotide reductase. Knockdown of this enzyme using RNA interference and other known chemical inhibitors exerted a similar effect to HU in combination with TMZ both in culture and in vivo. Conclusions We demonstrate preclinical efficacy of repurposing hydroxyurea in combination with TMZ for adjuvant GBM therapy. This combination benefit is of direct clinical interest given the extensive use of TMZ and the associated problems with TMZ-related resistance and treatment failure
Multiplex blood reporters for simultaneous monitoring of cellular processes
Contains fulltext :
125685.pdf (publisher's version ) (Open Access)Reporters secreted into the conditioned medium of cells in culture or into blood in vivo have shown to be useful tools for simple and noninvasive monitoring of biological processes in real-time. Here, we characterize the naturally secreted Vargula luciferase as a secreted blood reporter and show that this reporter can be multiplexed with the secreted Gaussia luciferase and alkaline phosphatase for simultaneous monitoring of three different cellular processes in the same biological system. We applied this system to monitor the response of three different subsets of glioma cells to a clinically relevant chemotherapeutic agent in the same well in culture or animal in vivo. This system could be extended to any field to detect multiple processes in the same biological system and is amenable for high-throughput screening to find drugs that affect multiple cellular populations/phenomena simultaneously
Multiplex Blood Reporters for Simultaneous Monitoring of Cellular Processes
Reporters secreted into the conditioned
medium of cells in culture
or into blood in vivo have shown to be useful tools for simple and
noninvasive monitoring of biological processes in real-time. Here,
we characterize the naturally secreted <i>Vargula</i> luciferase
as a secreted blood reporter and show that this reporter can be multiplexed
with the secreted <i>Gaussia</i> luciferase and alkaline
phosphatase for simultaneous monitoring of three different cellular
processes in the same biological system. We applied this system to
monitor the response of three different subsets of glioma cells to
a clinically relevant chemotherapeutic agent in the same well in culture
or animal in vivo. This system could be extended to any field to detect
multiple processes in the same biological system and is amenable for
high-throughput screening to find drugs that affect multiple cellular
populations/phenomena simultaneously